J.W. Cole Advisors Inc. Makes New Investment in TransMedics Group, Inc. (NASDAQ:TMDX)

J.W. Cole Advisors Inc. purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 14,305 shares of the company’s stock, valued at approximately $2,155,000.

Several other hedge funds and other institutional investors have also made changes to their positions in TMDX. O Neil Global Advisors Inc. purchased a new stake in TransMedics Group during the 2nd quarter worth approximately $1,604,000. Federated Hermes Inc. purchased a new stake in shares of TransMedics Group during the second quarter worth $3,349,000. Oppenheimer & Co. Inc. raised its stake in shares of TransMedics Group by 58.6% in the second quarter. Oppenheimer & Co. Inc. now owns 42,145 shares of the company’s stock valued at $6,348,000 after acquiring an additional 15,575 shares in the last quarter. Nicholas Investment Partners LP boosted its holdings in TransMedics Group by 44.9% in the second quarter. Nicholas Investment Partners LP now owns 85,391 shares of the company’s stock valued at $12,862,000 after purchasing an additional 26,470 shares during the period. Finally, VitalStone Financial LLC acquired a new position in TransMedics Group during the 2nd quarter worth $347,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Insider Activity at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $8,948,714.31. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $145.17, for a total value of $1,252,091.25. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,948,714.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total transaction of $463,725.66. Following the completion of the transaction, the insider now directly owns 20,843 shares in the company, valued at $3,267,557.11. The disclosure for this sale can be found here. Insiders sold a total of 52,622 shares of company stock valued at $8,327,633 in the last three months. 7.00% of the stock is currently owned by company insiders.

TransMedics Group Stock Up 1.5 %

Shares of NASDAQ:TMDX opened at $151.42 on Friday. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67. The firm has a 50 day simple moving average of $154.20 and a 200-day simple moving average of $126.66. The company has a market capitalization of $5.05 billion, a PE ratio of -445.35 and a beta of 1.99. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $177.37.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. The firm had revenue of $114.30 million during the quarter, compared to analysts’ expectations of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. TransMedics Group’s quarterly revenue was up 117.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.03) earnings per share. On average, equities analysts predict that TransMedics Group, Inc. will post 1.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TMDX has been the topic of a number of analyst reports. Morgan Stanley increased their price target on TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Piper Sandler lifted their price target on shares of TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Canaccord Genuity Group increased their price objective on shares of TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Stephens raised their price objective on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Finally, TD Cowen boosted their target price on shares of TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, June 7th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, TransMedics Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $171.44.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.